ASCO: Follow-up of Anti-CD19

Long-term follow-up of anti-CD19 CAR T-cell therapy for B-cell lymphoma and chronic lymphocytic leukemia.

Abstract No : 3012

Abstract Type : Poster Discussion Session

Indication : Diffused Large B-Cell Lymphoma (DLBCL)

Intervention : CAR T cells

Technology : CAR T Cell Therapy


Of the 43 treated patients, 63% had chemotherapy-refractory lymphoma. Patients had received a median of 4 previous lines of therapy. The median CAR+ T cell dose per kilogram was 2X10^6. The overall remission rate was 76% with 54% complete remissions (CR) and 22% partial remissions (PR). Patients with CR had higher median peak blood CAR levels (86 CAR+ cells/µL) than those who did not have CR (16 CAR+ cells/µL, P= 0.0041). Long-term adverse effects were rare except for B-cell depletion and hypogammaglobulinemia, which both improved over time.


This is the longest follow-up study of patients who received anti-CD19 CAR T cells. Anti-CD19 CAR T cells cause highly durable remissions of relapsed B-cell lymphoma and CLL, and long-term adverse effects of anti-CD19 CAR T cells were rare and usually mild.


97 mos remission strengthen efficacy claims of CAR T cell therapies in DLBCL.

Refer to Diffuse Large B-Cell Lymphoma Market report for detailed Insights.